GlassScriptPhysician profile
Tyler Lee Davis
NPI 1679734891
$12,732.22
in general payments reported to CMS, 2019-2025
73 companies · $3,654 in 2025
The $3,654 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,613 · 2023: $3,849 · 2024: $3,617 · 2025: $3,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,119.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $883.59 | 2022-2025 | Calquence, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $872.89 | 2022-2025 | |
| Janssen Biotech, INC. | $609.05 | 2022-2025 | Tecvayli, Erleada, Darzalex |
| Merck Sharp & Dohme LLC | $568.85 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $504.20 | 2022-2025 | |
| Daiichi Sankyo INC. | $476.62 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $469.10 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Regeneron Healthcare Solutions, INC. | $451.08 | 2022-2025 | Libtayo |
| Beigene USA, INC. | $362.99 | 2022-2024 | Brukinsa |
| Glaxosmithkline, LLC. | $343.77 | 2023-2025 | Ojjaara, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $335.80 | 2022-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $317.06 | 2022-2025 | Jakafi, Monjuvi |
| Eisai INC. | $308.95 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $307.21 | 2023-2025 | Xpovio |
| Galvanize Therapeutics, INC | $293.07 | 2023-2025 | Aliya System |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $283.37 | 2022-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Rigel Pharmaceuticals, INC. | $273.44 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Abbvie INC. | $269.82 | 2024-2025 | |
| Astellas Pharma US INC | $268.18 | 2022-2025 | Xtandi, Xospata, Vyloy |
| Sobi, INC | $256.46 | 2023-2025 | |
| Seagen INC. | $253.35 | 2022-2023 | Adcetris, Tivdak, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $229.53 | 2022-2025 | |
| Beone Medicines USA, INC. | $214.79 | 2025 | Tevimbra, Brukinsa |
| Ipsen Biopharmaceuticals, INC | $211.04 | 2022-2025 | Onivyde, Somatuline Depot, Tazverik |
| Gilead Sciences, INC. | $205.57 | 2022-2023 | Trodelvy |
| Genmab U.S., INC. | $156.90 | 2024-2025 | Epkinly |
| Genzyme Corporation | $155.86 | 2022-2025 | |
| Lilly USA, LLC | $154.97 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Puma Biotechnology, INC. | $151.63 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $145.34 | 2022-2023 | Imbruvica, Epkinly |
| Intuitive Surgical, INC. | $144.60 | 2022 | |
| Blueprint Medicines Corporation | $118.45 | 2023-2025 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $118.34 | 2022-2025 | Fotivda |
| Servier Pharmaceuticals LLC | $115.32 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.39 | 2023-2024 | Gilotrif |
| Stemline Therapeutics INC. | $100.70 | 2023-2025 | Orserdu |
| Kite Pharma, INC. | $97.45 | 2022-2025 | Yescarta |
| Genentech USA, INC. | $97.35 | 2023-2025 | Venclexta, Tecentriq, Perjeta |
| Amgen INC. | $90.00 | 2022-2023 | Kyprolis, Blincyto, Prolia |
| Alexion Pharmaceuticals, INC. | $88.66 | 2023-2024 | Ultomiris |
| Coherus Oncology, INC. | $88.62 | 2023-2024 | |
| Immunocore Limited | $88.14 | 2023 | Kimmtrak |
| Taiho Oncology, INC. | $82.69 | 2022-2025 | |
| Array Biopharma INC | $76.54 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Tempus Ai, INC | $74.63 | 2024 | |
| Recordati_rare_diseases_inc. | $64.16 | 2023-2024 | Sylvant |
| Jazz Pharmaceuticals INC. | $58.95 | 2024-2025 | |
| Geron Corporation | $55.50 | 2025 | Rytelo |
| Alnylam Pharmaceuticals INC. | $50.67 | 2022-2025 | Givlaari |
| Csl Behring | $50.08 | 2023-2024 | Afstyla, Idelvion |
| Morphosys, US INC. | $48.64 | 2022-2023 | Monjuvi |
| Exelixis INC. | $47.88 | 2025 | Cabometyx |
| Emd Serono, INC. | $42.33 | 2024-2025 | |
| Mirati Therapeutics, INC. | $42.02 | 2023 | Krazati |
| Foundation Medicine, INC. | $39.95 | 2023 | |
| Dendreon Pharmaceuticals LLC | $35.00 | 2024 | Provenge |
| Sumitomo Pharma America, INC. | $33.59 | 2025 | Orgovyx |
| Legend Biotech USA INC. | $28.26 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $27.37 | 2024 | Qinlock |
| Pharmacosmos Therapeutics INC. | $26.89 | 2023 | Monoferric |
| Fennec Pharmaceuticals, INC. | $25.77 | 2025 | Fyarro |
| G1 Therapeutics, INC. | $24.67 | 2022 | |
| Adaptive Biotechnologies Corporation | $24.55 | 2023 | Clonoseq |
| Iovance Biotherapeutics, INC. | $23.49 | 2025 | Amtagvi |
| Progenics Pharmaceuticals, INC. | $23.49 | 2022 | |
| Blue Earth Diagnostics | $22.93 | 2023 | |
| Accord Healthcare, INC. | $22.81 | 2025 | |
| Azurity Pharmaceuticals, INC. | $22.32 | 2025 | Danziten |
| Springworks Therapeutics, INC. | $21.73 | 2024 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $19.65 | 2024 | Pyrukynd |
| Kyowa Kirin, INC. | $17.14 | 2024 | Poteligeo |
| Adc Therapeutics America, INC. | $13.02 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.